Control Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Control Empresarial De Capital acquired 1,032,218 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The shares were acquired at an average cost of $0.61 per share, with a total value of $629,652.98. Following the transaction, the insider now directly owns 72,592,325 shares in the company, valued at $44,281,318.25. The trade was a 1.44 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Control Empresarial De Capital also recently made the following trade(s):

• On Monday, April 14th, Control Empresarial De Capital purchased 268,105 shares of ProKidney stock. The stock was bought at an average price of $0.73 per share, for a total transaction of $195,716.65.

ProKidney Trading Down 0.6 %

NASDAQ PROK traded down $0.01 on Friday, reaching $0.79. The company's stock had a trading volume of 1,018,709 shares, compared to its average volume of 687,286. The firm has a market cap of $231.49 million, a PE ratio of -1.44 and a beta of 1.52. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $4.44. The business has a 50-day moving average price of $1.03 and a 200 day moving average price of $1.51.

ProKidney (NASDAQ:PROK - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.08 million during the quarter. Analysts anticipate that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ProKidney

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. raised its stake in shares of ProKidney by 48.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 844,277 shares of the company's stock valued at $740,000 after acquiring an additional 275,630 shares during the last quarter. ProShare Advisors LLC raised its position in ProKidney by 57.3% in the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock valued at $52,000 after purchasing an additional 11,250 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in ProKidney by 17.3% in the fourth quarter. Nuveen Asset Management LLC now owns 266,366 shares of the company's stock worth $450,000 after purchasing an additional 39,216 shares in the last quarter. Bleichroeder LP increased its stake in shares of ProKidney by 8.4% in the fourth quarter. Bleichroeder LP now owns 2,000,000 shares of the company's stock valued at $3,380,000 after buying an additional 155,000 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of ProKidney by 3.2% in the fourth quarter. Bank of America Corp DE now owns 539,232 shares of the company's stock valued at $911,000 after buying an additional 16,538 shares during the last quarter. 51.59% of the stock is currently owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.